As a result, ICIs including the anti-PD-L1 antibody atezolizumab (2), the anti-PD-1 antibody pembrolizumab (3), and the anti-CTLA-4 antibody ipilimumab (4), have been approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for various cancer types (5). The gene discussed is CD274; the disease is cancer.